Jump to content

Allurar rigakafin globulin

Daga Wikipedia, Insakulofidiya ta kyauta.
Allurar rigakafin globulin
Bayanai
Ƙaramin ɓangare na antiserum (en) Fassara
Medical condition treated (en) Fassara Agana

Ana yin allurar rigakafi ta globulin ( VIG ) daga tarin jinin mutanen da aka yiwa allurar rigakafin cutar sankarau . Kwayoyin rigakafin waɗannan mutane da aka samar domin amsar maganin ƙwayar cuta ana cire su kuma ana tsarkake su. Wannan yana haifar da VIG. Ana iya gudanar da shi ta cikin jini. Ana amfani da shi don kula da mutanen da suka sami ci gaba na rigakafi bayan rigakafin ƙwayar cuta.

An kuma yi amfani da shi tare da cidofovir don barkewar cutar sankarau ta Midwest ta 2003 a matsayin magani tare don rage mummunar illar rigakafin cutar sankarau. [1] [2] Bugu da kari, CDC ta bayyana cewa ana iya la'akari da amfani da VIGIV don rigakafin kamuwa da cutar kyandar biri a cikin mutanen da aka fallasa waɗanda ba za su iya samun rigakafin cutar bayan bayyanar da maganin ƙanƙara ba saboda tsananin ƙarancin aikin T-cell.[3] [4]

Mummunan illar rigakafin cutar sankarau

[gyara sashe | gyara masomin]

Ga ƙaramin kaso na yawan jama'a, maganin ƙanƙara ko dai ba ya "ɗauka" ko kuma yana haifar da munanan al'amura . Waɗannan sun haɗa da cututtukan ƙwayoyin cuta na tsakiya na gaba, alurar riga kafi, eczema vaccintum, implantation na bazata, "gaɗaɗɗen alurar riga kafi", da rashes na erythematous ko urticarial na kowa.[5] [6] [7] [8]

Ci gaban rigakafi globulin

[gyara sashe | gyara masomin]

A ƙarshen 1940s, Henry Kempe ya ba da shawarar cewa maganin rikice-rikicen rigakafin ƙwayar cuta shine samar da ƙwayoyin rigakafi a cikin nau'in gamma globulin, magani na likita wanda aka sani da rigakafi mara kyau . [9] [10] Kempe ya lura cewa ga wasu jarirai, maganin furucin ya kasa "ɗauka". Kempe ya yi imanin wannan gazawar na iya kasancewa saboda yawan matakan rigakafin rigakafi na uwa zuwa alurar riga kafi a cikin jinin jarirai. Ya bayyana ga Kempe cewa kasancewar ƙwayoyin rigakafi sun toshe kwafin kwayar cuta, sabili da haka zubar da ƙwayoyin rigakafi daga mutanen da ke da rigakafi saboda rigakafin zai taimaka wa waɗanda allurar rigakafin ta gaza. [11]

Magungunan ƙwayoyin cuta guda biyu na VIG (VIGIV Cangene da VIGIV Dynport) sun sami lasisi ta FDA don kula da marasa lafiya da ke da ci gaba da alurar riga kafi, eczema alurar riga kafi, ƙwayar cuta ta gabaɗaya, da kuma shigar da ƙasa mai yawa ko sanyawa na lokaci-lokaci bin inoculation ba da gangan ba. [12] [13]

Cangene (wani reshe na Emergent BioSolutions) iri-suna VIGIV kuma ana san shi da wani madadin suna: C-VIG; CNJ 016; NP 016 - Cangene; VIG; VIGIV - Abubuwan Halittu na gaggawa. [14] An yi amfani da irin wannan nau'in magani da ake kira antiserum a cikin jiyya da yawa cikin nasara, kuma an kammala wasu bincike da gwaje-gwaje na asibiti don amfani da shi wajen magance cutar kyandar biri. [15]

An sabunta binciken farko na tallace-tallace a cikin 2021 don tabbatar da fa'idodin asibiti na VIGIV (CNJ-016, Vaccinia Immune Globulin Intravenous (Dan Adam), maganin bakararre) a cikin ƙudurin rikice-rikicen da ke haifar da alurar rigakafin Orthopoxvirus a cikin marasa lafiya da suka cancanta bi da VIGIV mai suna Clinical Sakamako na VIGIV Maganin Maganin Cutar Kanjamau ko Kamuwar Alurar riga kafi .

Alurar rigakafin Orthopoxvirus

[gyara sashe | gyara masomin]

Ana ba da shawarar allurar rigakafi na globulin (VIGIV) azaman layin farko na jiyya don magance mummunan halayen da ke haifar da ci gaba da kwafin ƙwayar cutar alurar riga kafi bayan yin allurar ta amfani da ACAM2000 ko APSV. [16] [17] [18] [19] [20]

Ba a samun VIGIV na kasuwanci amma ana iya samarwa ta hanyar Strategic National Stockpile (SNS) don magance rikice-rikicen rigakafin cutar sankarau a cikin marasa lafiya da alamun bayyanar asibiti.

Sauran jiyya sune

  • Cidofovir
  • Brincidofovir (TEMBEXA)
  • Tecovirimat (ST-246 ko sunan sa Tpoxx)

Ana samun jagororin sarrafa maganin rigakafin Orthopoxvirus (Smallpox) daga Cibiyar Kula da Cututtuka da Cututtuka. [21]

Littattafan da aka ci gaba da cutar sasanta: Caseply Case da magani-shiryayyar rigakafi tare da Alcta idan basu da lafiya. [22]

Mutanen da ke da cutar HIV da AIDS suna cikin haɗarin haɓaka halayen halayensu da lahani yayin da suke da Orthopoxvirus. Littattafai irin su Progressive Vaccinia An samu ta hanyar Zoonotic Transmission a cikin Mara lafiya mai HIV/AIDS ya sake bayyana a cikin sharuddan asibiti dalilin da ya sa marasa lafiya da ke da ƙarancin rigakafi (daga kamuwa da cutar HIV, ko kuma daga duk wani yanayin kiwon lafiya da ke shafar tsarin rigakafi) suna cikin haɗari mai yawa. [23] Hakazalika, jarirai (da kuma ta tsawaita a lokacin daukar ciki), da kuma tsofaffi tare da yanayin kiwon lafiya da suka rigaya sun fi dacewa da halayen halayen. [24] Ga mutanen da ke shan maganin rigakafi don ƙarancin rigakafi, VIGIV yana da suna daban kuma yana ga takamaiman yanayin (idan sun sami necrosis daga maganin ƙanƙara) maimakon magani na gabaɗaya don rashin ƙarfi. [25] Wadannan ( IgG, IgA, IgM, IgD, da IgE ) a baya an yi bincike don amfani da kwayar cutar Vaccinia Ankara, fiye da VIGIV a matsayin maganin cutar sankarau. [26] [27]

Duba kuma

[gyara sashe | gyara masomin]
  • Cangene
  • Eczema alurar riga kafi
  • Gamma globulin
  • Immunoglobulin far - bayyani na wannan batu.
  • Alurar riga kafi

Hanyoyin haɗi na waje

[gyara sashe | gyara masomin]
  • Maurer, Douglas M; Harrington, Brian; Lane, J Michael (1 September 2003). "Smallpox vaccine: contraindications, administration, and adverse reactions". American Family Physician. 68 (5): 889–896. PMID 13678138. Samfuri:ProQuest.
  • CDC Smallpox Home
  • Quick Guide to Preexposure Smallpox Vaccination
  • U.S. Food and Drug Administration – Vaccinia Immune Globulin Intravenous (Human) Supporting Documents older than three years
  • Vaccinia Immune Globulin Intravenous Product Information (this pamphlet is included with the medicine)

Manazarta

[gyara sashe | gyara masomin]
  1. ↑ "CDC Smallpox | Investigational Vaccinia Immune Globulin (VIG) Information". Bt.cdc.gov. Archived from the original on 2013-05-10. Retrieved 2013-06-16.
  2. ↑ Wharton, M; Strikas, RA; Harpaz, R; Rotz, LD; Schwartz, B; Casey, CG; Pearson, ML; Anderson, LJ (4 April 2003). "Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC)". MMWR. Recommendations and Reports. 52 (RR-7): 1–16. PMID 12710832.
  3. ↑ "Vaccinia Immune Globulin IV Monograph for Professionals". Drugs.com.
  4. ↑ "Monkeypox | Agent Fact Sheet". 17 August 2023.
  5. ↑ Lane, J.Michael; Goldstein, Joel (July 2003). "Adverse events occurring after smallpox vaccination". Seminars in Pediatric Infectious Diseases. 14 (3): 189–195. doi:10.1016/s1045-1870(03)00032-3. PMID 12913830.
  6. ↑ Frelinger, JA; Garba, ML (29 August 2002). "Responses to smallpox vaccine". The New England Journal of Medicine. 347 (9): 689–90, author reply 689-90. doi:10.1056/NEJM200208293470913. PMID 12201305.
  7. ↑ Møller-Larsen, A; Haahr, S (January 1978). "Humoral and cell-mediated immune responses in humans before and after revaccination with vaccinia virus". Infection and Immunity. 19 (1): 34–39. doi:10.1128/iai.19.1.34-39.1978. PMC 414044. PMID 624594.
  8. ↑ Cohen, Jon (2 November 2001). "Smallpox Vaccinations: How Much Protection Remains?". Science. 294 (5544): 985. doi:10.1126/science.294.5544.985. PMID 11691969. S2CID 28270372.
  9. ↑ "Vaccinia immune globulin definition - Medical Dictionary definitions of popular medical terms easily defined on MedTerms". Medterms.com. 2012-06-14. Archived from the original on 2012-08-09. Retrieved 2013-06-16.
  10. ↑ "CDC Smallpox | Medical Management of Smallpox (Vaccinia) Vaccine Adverse Reactions (Info for Clinicians and Public Health Professionals)". Bt.cdc.gov. Archived from the original on 2013-06-02. Retrieved 2013-06-16.
  11. ↑ Bray, M. (15 September 2004). "Henry Kempe and the Birth of Vaccinia Immune Globulin". Clinical Infectious Diseases. 39 (6): 767–769. doi:10.1086/423005. PMID 15472805.
  12. ↑ Wittek, Riccardo (1 May 2006). "Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy". International Journal of Infectious Diseases. 10 (3): 193–201. doi:10.1016/j.ijid.2005.12.001. PMID 16564720.
  13. ↑ "DynPort Vaccine Company | GDIT".
  14. ↑ "DailyMed - CNJ-016 (Vaccinia immune globulin- human injection".
  15. ↑ Leendertz, Siv; Stern, Daniel; Theophil, Dennis; Anoh, Etile; Mossoun, Arsène; Schubert, Grit; Wiersma, Lidewij; Akoua-Koffi, Chantal; Couacy-Hymann, Emmanuel; Muyembe-Tamfum, Jean-Jacques; Karhemere, Stomy; Pauly, Maude; Schrick, Livia; Leendertz, Fabian; Nitsche, Andreas (29 September 2017). "A Cross-Sectional Serosurvey of Anti-Orthopoxvirus Antibodies in Central and Western Africa". Viruses. 9 (10): 278. doi:10.3390/v9100278. PMC 5691630. PMID 28961172.
  16. ↑ "Medical Management of Adverse Reactions to Vaccinia Virus Vaccination | Smallpox | CDC". 2 November 2021.
  17. ↑ "Progressive Vaccinia - an overview | ScienceDirect Topics".
  18. ↑ "VIGIV (Vaccinia immune globulin intravenous) dosing, indications, interactions, adverse effects, and more".
  19. ↑ Eggleton, J. S.; Nagalli, S. (2022). "Highly Active Antiretroviral Therapy (HAART)". StatPearls. StatPearls. PMID 32119420.
  20. ↑ Izzedine, Hassane; Launay-Vacher, Vincent; Baumelou, Alain; Deray, Gilbert (August 2004). "Antiretroviral and immunosuppressive drug-drug interactions: An update". Kidney International. 66 (2): 532–541. doi:10.1111/j.1523-1755.2004.00772.x. PMID 15253704.
  21. ↑ "Medical Management of Adverse Reactions to Vaccinia Virus Vaccination | Smallpox | CDC". 2 November 2021.
  22. ↑ Lederman, E. R.; Davidson, W.; Groff, H. L.; Smith, S. K.; Warkentien, T.; Li, Y.; Wilkins, K. A.; Karem, K. L.; Akondy, R. S.; Ahmed, R.; Frace, M.; Shieh, W.-J.; Zaki, S.; Hruby, D. E.; Painter, W. P. (1 November 2012). "Progressive Vaccinia: Case Description and Laboratory-Guided Therapy With Vaccinia Immune Globulin, ST-246, and CMX001". Journal of Infectious Diseases. 206 (9): 1372–1385. doi:10.1093/infdis/jis510. PMC 3529603. PMID 22904336.
  23. ↑ Laiton-Donato, Katherine; Ávila-Robayo, Paola; Páez-Martinez, Andrés; Benjumea-Nieto, Paula; Usme-Ciro, José A.; Pinzón-Nariño, Nicole; Giraldo, Ivan; Torres-Castellanos, Diego; Nakazawa, Yoshinori; Patel, Nishi; Wilkins, Kimberly; Li, Yu; Davidson, Whitni; Burgado, Jillybeth; Satheshkumar, Panayampalli Subbian (March 2020). "Progressive Vaccinia Acquired through Zoonotic Transmission in a Patient with HIV/AIDS, Colombia". Emerging Infectious Diseases. 26 (3): 601–605. doi:10.3201/eid2603.191365. PMC 7045850. PMID 32091366.
  24. ↑ Bray, Mike; Wright, Mary E. (15 March 2003). "Progressive Vaccinia". Clinical Infectious Diseases. 36 (6): 766–774. doi:10.1086/374244. PMID 12627361.
  25. ↑ "Specific Antibody Deficiency | Immune Deficiency Foundation".
  26. ↑ Earl, Patricia L.; Americo, Jeffrey L.; Wyatt, Linda S.; Anne Eller, Leigh; Montefiori, David C.; Byrum, Russ; Piatak, Michael; Lifson, Jeffrey D.; Rao Amara, Rama; Robinson, Harriet L.; Huggins, John W.; Moss, Bernard (15 September 2007). "Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate". Virology. 366 (1): 84–97. doi:10.1016/j.virol.2007.02.041. PMC 2077303. PMID 17499326.
  27. ↑ Berger, Melvin (1 May 2008). "Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency". Immunology and Allergy Clinics of North America. 28 (2): 413–437. doi:10.1016/j.iac.2008.01.008. PMC 7127239. PMID 18424340.
Daga "https://ha.wikipedia.org/w/index.php?title=Allurar_rigakafin_globulin&oldid=505154"